Clinical Trial
Share your love
PRIMAvera study: Central vision improvement with subretinal implant | Ophthalmology Times
The implant is shown placed subretinally in an eye with geographic atrophy due to age-related macular degeneration. (Image courtesy of Frank G. Holz, MD, FEBO, FARVO) (PRIMA) system implant restored central vision and led to a significant improvement in visual…
The year in optometry: 10 stories that defined eye care in 2025 | Ophthalmology Times
(Image Credit: AdobeStock) The past year marked a pivotal period for optometry, with 2025 delivering meaningful clinical, regulatory, and legislative developments that reshaped eyecare practice. Innovation remained front and center as the US FDA authorized Essilor’s Stellest lenses for myopia…
Adopting Emerging Therapies in Dry Eye Care | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Evaluating Retinal Drying, Durability and IOP Management with Second-Generation Anti-VEGF Therapies in Retinal Vascular Diseases | Ophthalmology Times
This segment examines real-world comparisons between faricimab and aflibercept 8 mg in terms of retinal drying, durability, and intraocular pressure (IOP) management. Clinicians note that both agents extend treatment intervals modestly—often by about one additional week compared with standard 2…
How AI is reshaping ophthalmology in 2025 and beyond | Ophthalmology Times
(Image Credit: AdobeStock/ImageFlow) Artificial intelligence (AI) continues to evolve with improved diagnostic abilities, individualized patient treatments, and enhanced surgical accuracy. Some key developments include the analysis of retinal scans that provide earlier disease detection and the ability to spot tumors…
8 things to know about aflibercept 8 mg for retinal vascular disease | Ophthalmology Times
The US Food and Drug Administration (FDA) approved aflibercept 8 mg (EYLEA HD) for the treatment of patients with macular edema following retinal vein occlusion (RVO) with up to 8-week dosing after an initial dosing period last month. The latest…
From bench to bedside: Evolving realities of gene therapy for inherited retinal diseases | Ophthalmology Times
(Image Credit: AdobeStock/artacet) In recent years, gene therapy has emerged from the shadows of theoretical potential into the spotlight of clinical reality. The approval of voretigene neparvovec-rzyl (Luxturna; Spark Therapeutics) marked a historic moment as the first gene therapy for…
The Atrophy Advisor: An online tool to inform GA treatment decisions | Ophthalmology Times
(Image Credit: AdobeStock/NINENII) An online tool, Atrophy Advisor, was developed to guide physicians regarding treatments for patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD). The tool, available at atrophyadvisor.com, integrates GA progression and personalized lifespan estimates to…
NCX 470 advances toward US, China NDA submissions for NCX 470 | Ophthalmology Times
(Image Credit: AdobeStock) Nicox has announced it has acquired and analyzed all key data required to support the submission of New Drug Applications (NDAs) in the US and China for NCX 470.1 NCX 470 is Nicox’s lead clinical product candidate…
Unmet Needs in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…